AstraZeneca Pharma India net profit down 45 percent to Rs 10.24 crore in Q1
New Delhi: Drug firm AstraZeneca Pharma India on Monday reported a 45.03 per cent decline in its net profit to Rs 10.24 crore for the June ended quarter.
The company had posted a net profit of Rs 18.63 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing.
Revenue from operations stood at Rs 175.40 crore for the quarter under consideration. It was Rs 193.57 crore for the same period a year ago, it added.
Read also: AstraZeneca Saphnelo gets USFDA nod for treating Systemic Lupus Erythematosus
The company's board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2021-22, the filing said.
Read also: AstraZeneca India, BHU conduct cancer screening camp for women in Varanasi
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.